elranatamab

Details

Files
Generic Name:
elranatamab
Project Status:
Active
Therapeutic Area:
Relapsed or refractory multiple myeloma
Manufacturer:
Pfizer Canada ULC
Call for patient/clinician input open:
Brand Name:
Elrexfio
Project Line:
Reimbursement Review
Project Number:
PC0315-000
Call for patient/clinician input closed:
Tumour Type:
Myeloma
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input openSeptember 05, 2023
Call for patient/clinician input closedOctober 30, 2023
Clarification:

- Patient input submission received from Myeloma Canada

Submission receivedNovember 09, 2023
Submission acceptedNovember 24, 2023
Review initiatedNovember 27, 2023
Draft CADTH review report(s) provided to sponsor for commentFebruary 23, 2024
Deadline for sponsors commentsMarch 05, 2024
CADTH review report(s) and responses to comments provided to sponsorMarch 28, 2024
Expert committee meeting (initial)April 10, 2024
Draft recommendation issued to sponsorApril 23, 2024
Draft recommendation posted for stakeholder feedbackMay 02, 2024
End of feedback periodMay 16, 2024
Final recommendation issued to sponsor and drug plansMay 31, 2024